The manufacturer of Palforzia has announced that worldwide production will cease, advising services not to begin new patients on Palforzia after April 2026. Peanut allergy is the most extensively studied food allergen for oral immunotherapy (OIT), with robust safety and efficacy data spanning many years. Prof Du Toit and Dr Foong have contributed to landmark research in this field, and at the Allergy Centre of Excellence we provide substantial peanut OIT experience as one of the largest former Palforzia providers.

Lessons from Palforzia

Safety: pharmaceutical-grade, characterised allergens with consistent protein ratios proved essential for safe, predictable dosing — principles now applied to non-commercialised peanut products.
“Bite protection” goals: treatment success doesn’t require complete tolerance. Reaching thresholds of 600–1,000 mg (roughly 2–4 peanuts) provides meaningful protection against accidental contamination.
Early intervention: younger cohorts show higher desensitisation rates and better safety than adolescents.
Dose forgiveness: after roughly two years of maintenance, the immune system matures, allowing flexibility when a dose is occasionally missed.

Landmark publications

POSEIDON (NEJM Evidence): in toddlers aged 1–3, 73.5% achieved desensitisation to 600 mg.
PALISADE (NEJM, 2018): 67% of participants aged 4–17 tolerated 600 mg of peanut protein after one year, compared with only 4% on placebo.
ARTEMIS (Lancet Child & Adolescent Health, 2020): 58% of treated children tolerated a 1000 mg dose versus 2% for placebo.

Why is Palforzia leaving the market?

Despite its effectiveness, Palforzia demanded substantial commitments — multi-hour clinic visits for every dose increase, intensive senior staffing, and daily home dosing with a quiet observation period. Its exit reflects commercial considerations, not safety or efficacy concerns.

The peanut-flour approach

Precisely measured peanut flour enables tailored up-dosing schedules matched to each child, avoids commercial-market disruption, and integrates more manageably into family routines — delivered with expert oversight from consultants who pioneered the original Palforzia research. Non-Palforzia peanut OIT is available at the Allergy Centre of Excellence, with allergists, specialist nurses, dietitians, psychologists and a continuous emergency telephone line.